Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent

Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent

Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent

MC MD

Inclusion Criteria:

• Korean prostate cancer over 50 years old with pathological confirmation
• Patients receiving GnRH antagonist or GnRH agonist plus anti- androgen combination within 6 months since starting.
• Patients measured bone density level before starting to receive hormone therapies above.

Exclusion Criteria:

• Patients who are treated other anti-osteoporosis drugs and who are treated bisphosphate due to BMD T score below -3.0.
• Patients who are hard to be analysed by attach to other bone disease.
• Patients who are hard to be analysed by limitation of chart record according to investigators'discretion.